Drug Study Halted Early for Certain Covid-19 Patients After No Benefit Seen

Regeneron and Sanofi said they will shut down part of a study exploring whether their arthritis therapy could treat certain hospitalized Covid-19 patients because the drug looked unlikely to help them

Regeneron Pharmaceuticals Inc. and Sanofi SA said Monday they will shut down part of a study exploring whether their arthritis therapy could treat certain hospitalized Covid-19 patients because the drug looked unlikely to help them.

An early look at ongoing trial results indicated the therapy, named Kevzara, wasn’t helping patients who were hospitalized with a severe form of Covid-19 but don’t require a ventilator’s assistance with breathing, the companies said.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

WSJ /  🏆 98. in US

Canada Latest News, Canada Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Researchers should study how Covid-19 affects women'More research must be conducted to look into the potential impact of sex, along with other demographic factors, on Covid-19 patients,' writes former US Assistant Surgeon General Susan Blumenthal for CNNOpinion.
Read more »

Researchers studying a common heartburn drug as treatment for Covid-19Hospitals in New York are giving Covid-19 patients heartburn medicine to see if it helps fight the virus. Preliminary results of the clinical trial of famotidine, the active ingredient in Pepcid, could come out in the next few weeks.
Read more »